As another cancer maker, the interest in Galectin-3 (Gal-3) stems from the evidence that it is a pro-inflammatory sugar-binding protein involved in prostate cancer malignancy, and is considered to be a promising therapeutic target [7, 8]. Here, LGALS3 is linked to prostate carcinoma.